A multicenter, blinded, placebo-controlled study to investigate the effects of everolimus and/or BEZ235 on the immune response to vaccination in the elderly.

Trial Profile

A multicenter, blinded, placebo-controlled study to investigate the effects of everolimus and/or BEZ235 on the immune response to vaccination in the elderly.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs Dactolisib (Primary) ; Everolimus; Influenza virus vaccine (Afluria); Influenza virus vaccine (Afluria)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis Institutes for BioMedical Research
  • Most Recent Events

    • 08 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 21 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
    • 05 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top